<i>BRCA1</i> founder mutations and beyond in the Polish population: A single-institution <i>BRCA1/2</i> next-generation sequencing study

<div><p>Hereditary mutations in <i>BRCA1/2</i> genes increase the risk of breast cancer by 60–80% and ovarian cancer by about 20–40% in female carriers. Detection of inherited mutations in asymptomatic carriers allows for the implementation of appropriate preventive measures. <i>BRCA1/2</i> genotyping is also important for poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitor administration. This work addresses the need for next-generation sequencing (NGS) technology for the detection of <i>BRCA1/2</i> mutations in Poland where until recently mostly founder mutations have been tested, and whether <i>BRCA</i> diagnostics should be extended beyond the panel of founder mutations in this population. The study comprises 2931 patients who were referred for genetic counseling and tested for founder and recurrent mutations in <i>BRCA1</i> (5382insC (c.5266dupC; p.Gln1756Profs), c.5370C>T (c.5251C>T; p.R1751*), 300T>G (c.181T>G; p.Cys61Gly), 185delAG (c.68_69delAG; p.Glu23Valfs), and 4153delA (c.4035delA; p.Glu1346Lysfs)) by high-resolution melting/Sanger sequencing. A total of 103 (3.5%) mutations were detected, including 53 (51%) in healthy subjects and 50 (49%) in cancer patients. Then, based on more stringent clinical and pedigree criteria, sequencing of all <i>BRCA1/2</i> exons was performed in 454 (16%) patients without founder mutations by NGS, which detected 58 mutations (12.8%), 40 (8.8%) of which were pathogenic. In 14 (3.1%) subjects, variants of uncertain significance (VUS) were detected, and in four (0.9%) subjects, the detected mutations were benign. In total, 161 mutations were detected using our two-step algorithm (founder test and NGS), of which 64% were founder mutations, 25% were NGS-detected pathogenic mutations, 9% were VUS, and 2% were benign. In addition, 38 mutations not yet reported in the Polish population were detected. In total, founder mutations accounted for only 64% of all detected mutations, and the remaining mutations (36%) were dispersed across the <i>BRCA1/2</i> gene sequences. Thus, in Poland, testing for constitutional mutations in <i>BRCA1/2</i> should be carried out in two stages, where NGS is performed in qualifying subjects if founder mutations are not identified.</p></div

Frequencies of mutations detected with the screening test targeting founder and recurrent <i>loci</i> in <i>BRCA1</i> per year and total.

<p>Frequencies of mutations detected with the screening test targeting founder and recurrent <i>loci</i> in <i>BRCA1</i> per year and total.</p

Percentage share of all detected mutations with both the screening test (103) and NGS (58): Pathogenic (40), VUS (14), benign (4).

<p>Percentage share of all detected mutations with both the screening test (103) and NGS (58): Pathogenic (40), VUS (14), benign (4).</p

The frequency of mutations detected in <i>BRCA1/2</i> with NGS among 454 individuals, per year and total (2014–2016).

<p>The frequency of mutations detected in <i>BRCA1/2</i> with NGS among 454 individuals, per year and total (2014–2016).</p